Introduction
Sarcoidosis is a multisystem disease characterized by non-caseating granulomatous inflammation, with a wide array of manifestations and severity. Up to one-third of patients with sarcoidosis have cardiac involvement based on autopsy studies, although * 1 -5 Cardiac sarcoidosis (CS) diagnosed by endomyocardial biopsy is associated with sudden cardiac death and congestive heart failure (CHF). 5 -8 With advanced cardiac imaging, diagnosis of CS has become more common in subjects with preserved cardiac function. 9 In the era of increasing non-invasive diagnosis, few data exist to guide immunosuppression. To ascertain the impact of current management strategies on CS outcomes, we performed a comprehensive medical record review at two large academic medical centres.
Methods

Patient identification
Potential subjects were identified from two North American academic medical centres, the Mayo Clinic in Rochester, Minnesota, and the University of Calgary in Alberta. Subjects from Mayo Clinic were identified utilizing a clinical notes search tool. In the 'diagnosis' field of notes dated 1 January 1994 through 31 December 2014, the terms 'sarcoidosis' or 'sarcoid' along with 'block', 'cardiac', 'cardiomyopathy', or 'ventricular tachycardia' were sought, with or without 'cardiac sarcoidosis' in the 'impression/report/plan' field. At the University of Calgary, subjects were identified by expert review of established patient panels. This study was approved by Mayo Clinic Institutional Review Board (#14-005250). All patients provided informed consent for research inclusion. The investigation conforms with the principles outlined in the Declaration of Helsinki. Among those identified by the initial search, subjects were selected using the 2014 Heart Rhythm Society expert consensus criteria for the clinical or histological diagnosis of CS. 10 Only subjects having data from at least two time points or episodes of care were included in the analysis.
Analysis
A retrospective chart review was performed to collect demographics, disease characteristics, diagnostic evaluations, therapies, and outcomes. Following analyses of the entire cohort, the impact of immunosuppressive strategies was assessed. Patients were grouped based on therapy initiated within 90 days of diagnosis in order to assess the impact of early management strategies. A composite outcome of ventricular assist device (VAD) placement, heart transplant, or death was utilized. Continuous variables were compared among groups using the Kruskal-Wallis test. Categorical variables were compared using the Chi-square test. Kaplan-Meier analyses were used to estimate outcomes during the follow-up time after diagnosis. Log-rank tests were used to compare these curves among groups. Percentages are not provided for most comparisons as duration of follow-up varied among patients.
Results
Patient selection and treatment groups
A total of 574 patients were identified with the initial search ( Figure 1 ). Of these, 119 patients met the Heart Rhythm Society diagnostic criteria for CS. 10 Additional patients were excluded based on insufficient follow-up (n = 22), diagnosis from histopathology at the time of explant or left ventricular (LV) core for VAD placement (n = 4), and other diagnoses felt to be more clinically relevant than CS (arrhythmogenic right ventricular dysplasia, n = 1; hypertrophic obstructive cardiomyopathy, n = 1). The remaining 91 patients were included. The median duration of follow-up after CS diagnosis was 43.8 months (interquartile range 19.5-77.0). Median time from diagnosis of sarcoidosis to diagnosis of cardiac involvement was 1.0 month (0-36.6).
Because patients received a variety of immunosuppressive therapies (Table 1) , we pooled patients into three groups for analyses, based on therapy utilized within 90 days of CS diagnosis. Group 1 included subjects treated with prednisone only (n = 41); group 2, subjects receiving an immunosuppressive agent other than prednisone (so-called 'steroid sparing agent', with or without prednisone; n = 29); group 3, subjects who did not receive immunosuppressive therapy within 90 days of CS diagnosis (n = 21). Fourteen patients in group 3 were started on immunosuppression more than 90 days after CS diagnosis.
Among patients receiving prednisone within 90 days of CS diagnosis, median initial dose for those receiving prednisone only was 40 mg daily (interquartile range 40-60 mg), and 60 mg daily (20-90 mg) in those patients who received an additional immunosuppressive agent. Mycophenolate mofetil was the most commonly prescribed steroid sparing agent, with 1500 mg twice daily being the most common dose.
Baseline characteristics
Baseline demographics and diagnostic information are presented in Table 1 . The median age at diagnosis of CS was 51 years and 28.6% of patients were female. The majority of patients identified as Caucasian (74/91, 81.3%), while 10 of the 17 remaining patients identified as Black, four as Asian, and one each as Indian, Pakistani, and Trinidadian. Cardiomyopathy was the most frequent presenting manifestation, with 47 (51.6%) patients, while atrioventricular block was present in 31 (34.1%), ventricular arrhythmia in 22 (24.2%), and epicardial coronary disease in one (1.1%). Twenty patients (22.0%) had more than one feature of CS at the time of diagnosis. Twenty-two patients (24.2%) had a histological diagnosis of CS made by myocardial biopsies, 79 (86.8%) had extra-cardiac biopsies consistent with sarcoidosis, and 11 (12.1%) had findings compatible with sarcoidosis on biopsies from both myocardium and other sites. Thirteen patients (14.3%) met diagnostic criteria on the basis of abnormal cardiac magnetic resonance imaging (MRI) with no clinical manifestations of CS at the time of diagnosis. The median LV ejection fraction (LVEF) was 37%. Eighty-six of 91 subjects had extra-cardiac sarcoidosis, most often lung or mediastinal disease (82/91, 90.1%). A total of 48 of 91 patients underwent device placement (pacer or defibrillator) prior to or within 90 days of CS diagnosis, and 21 additional patients received a device later. Eighty-three of 91 (91.2%) received concurrent cardiac pharmacotherapy during follow-up, including at least one of the following: beta-blockade, angiotensin-converting enzyme inhibitor (or angiotensin receptor blockade), loop or thiazide diuretic, aldosterone antagonist, antiarrhythmic therapy.
Baseline characteristics were similar across the three treatment groups ( 
Pharmacotherapy by treatment group
The time from diagnosis of sarcoidosis to identification of cardiac involvement was longest in patients who were not initially treated for CS (P = 0.006). Neither the total duration of any immunosuppression, nor of prednisone, differed by treatment group. Additional details are included in Table 3 .
Heart failure and arrhythmia events
Among the 47 patients presenting with cardiomyopathy, 31 experienced improvement in LVEF of ≥ 10% during follow-up. There was no difference across treatment groups in the time to improvement (log-rank = 0.38). Conversely, 23 of 47 had a decline in LVEF reports. There was no significant difference in the time to these events by treatment group, but the majority of events seemed to occur within the first year of follow-up (log-rank = 0.20). Unlike the CHF outcomes, among all 91 patients, those receiving steroid sparing agents were more likely to have arrhythmia events during follow-up (log-rank < 0.001) (Figure 2) . During a median follow-up of 35 months for the 13 patients meeting diagnostic criteria based on abnormal imaging, four went on to develop clinical CS. One patient developed ventricular arrhythmia 12.5 months after CS diagnosis, while three developed cardiomyopathy at 19.5, 22.3 , and 56.0 months. Treatment in this group of 13 varied. Among the four patients who 
Ventricular assist device placement, transplantation, and death
During a median follow-up of 43.8 months, 14 of the entire 91 patients reached the composite endpoint of VAD placement, heart transplant, and/or death. Eleven of 47 patients presenting with cardiomyopathy, five of 22 presenting with arrhythmia, and two of 31 presenting with atrioventricular block went on to reach the composite endpoint. Among these, three of the five presenting with arrhythmia, and one of the patients presenting with atrioventricular . block, also had cardiomyopathy at diagnosis. One patient with atrioventricular block at diagnosis and two with ventricular arrhythmia at diagnosis went on to reach the composite endpoint after later developing cardiomyopathy. Taken together, either at diagnosis or developing later, all 14 patients reaching the composite endpoint had cardiomyopathy, and nine of the 14 patients had ventricular arrhythmia. None of the 13 patients who had been diagnosed with CS on the basis of imaging alone reached the composite endpoint. Specific outcomes are outlined in Table 4 . In six of the seven patients who died during follow-up, cause of death was progressive CHF. Survival without composite outcome did not differ by treatment group (log-rank = 0.17) (Figure 3) . Patients with cardiomyopathy at diagnosis (n = 47 vs. 44 without) were more likely to reach the composite endpoint (log-rank = 0.005) (Figure 4) . Presentation with atrioventricular block (n = 31 vs. 60 without), or ventricular arrhythmia (n = 22 vs. 69 without) did not clearly affect the likelihood of meeting the composite endpoint (log-rank = 0.07 and 0.64, respectively).
Presence of a device prior to or within 90 days of diagnosis (pacer and/or defibrillator vs. not; n = 48 vs. 43) did not impact survival without composite endpoint (log-rank =0.28). Among those with a device there was no difference in survival by treatment group (log-rank = 0.10).
Discussion
In this large case series, the clinical presentation of CS appeared to have a larger impact on outcomes than the treatment regimen. The majority of patients in our cohort received immunosuppressive therapy, across all disease manifestations. Interestingly, neither outcomes nor total duration of immunosuppression differed by initial treatment approach.
Despite most patients receiving immunosuppressive and adjunctive therapies, the rates of decline in LVEF and arrhythmia remained high. In comparison with older series in which all subjects were diagnosed by endomyocardial biopsy, the annual rates of death, transplantation, and VAD placement are lower. 5, 8 The reasons for this observation are not certain, but may reflect earlier diagnosis resulting in less severe disease in the current series. Consistent with this reasoning, CS subjects in this report had relatively preserved LVEF at time of diagnosis, with median LVEF of 37%, as compared to 31% in the study by Okura et al. 8 No treatment regimen was associated with a statistically better outcome in our series. This observation, combined with the high rates of decline in LVEF and arrhythmia, suggests that more work is needed to define the optimal immunosuppressive regimen for biopsy proven or probable CS. Although the baseline left and right ventricular function parameters, as well as the distribution of other manifestations, appeared similar across treatment groups, the higher rate of subsequent arrhythmia events among patients receiving steroid sparing agents is notable. It is possible that this reflects differing baseline disease severity that is not well captured by comparing the individual measures; perhaps a combination of features led . clinicians to start steroid sparing agents up front in patients they suspected to have particularly active disease. That 14 of 21 patients not initially treated with immunosuppression subsequently started on therapy more than 90 days from diagnosis also supports the concept that novel therapeutic strategies based on a mechanistic understanding of the disease are needed. The finding that the presence of cardiomyopathy at diagnosis was associated with worse outcome is consistent with that described by Zhou et al. 1 It is notable that the majority of patients who presented with cardiomyopathy and had follow-up LVEF assessment experienced an improvement in LVEF, also similar to their report, 1 including some who did not receive immunosuppression. With this observation, it is interesting that baseline LVEF did not appear to differ between patients who were and were not initially treated with immunosuppressive therapy. An additional consideration affecting this may be the estimated duration of LV dysfunction prior to the diagnosis of CS. In some cases, there was concern that the disease was 'burned out', that the phase of active inflammation had passed, and remodelling had already occurred. Patients who were not initially treated for CS had the longest median time between diagnosis of sarcoidosis and that of CS, which may suggest some degree of chronicity. It is also important to note that despite the apparent increase in LVEF observed in the majority of those presenting with cardiomyopathy, many patients, including those with normal LV function at diagnosis, went on to have subsequent decline in LV function. As this often occurred years after diagnosis, the appropriate duration of immunosuppressive therapy, if utilized, warrants evaluation as well.
In contrast, those with atrioventricular block at diagnosis were least likely to reach the composite endpoint and, as described above, both patients who did so had cardiomyopathy at the time. Notably, all patients with atrioventricular block at presentation underwent device placement (pacer +/-defibrillator). Thus, whether patients with atrioventricular block as the sole manifestation of CS should be grouped with patients having cardiomyopathy or ventricular arrhythmia, from the standpoint of both management decisions and outcome assessment, requires further exploration. In their recent analysis, Zhou et al. 1 found that device placement (including both pacemakers and defibrillators) was associated with improved survival. Additionally, Takada et al. 11 previously noted that among patients with pacemaker placement in CS, there appeared to be a survival advantage associated with use of corticosteroids. These differences were not observed in our cohort.
Advanced imaging techniques have taken on a greater role in the identification of cardiac involvement by sarcoidosis. We utilized the 2014 Heart Rhythm Society recommendations, which are similar to those outlined by the World Association for Sarcoidosis and Other Granulomatous Disorders (WASOG). 1, 12 While the clinical manifestations of CS are well-established, the role of imaging in diagnosis and treatment decision-making continues to evolve. Both positron emission tomography (PET) and MRI have been recognized to be sensitive modalities in CS.
13 -23 Both imaging modalities have been found to predict an increased risk of adverse outcomes in patients with sarcoidosis, including those without clear clinical features of cardiac involvement. 21, 24 The appropriate management of such patients is not yet entirely clear. As noted above, among the 13 patients in our cohort who met diagnostic criteria based on abnormal imaging without a clinical syndrome of CS, approximately one-third later developed compatible clinical features, occurring after one year or more. The combination of PET and MRI techniques, simultaneously or sequentially, has been described, and may be a fruitful approach going forward, capitalizing on the sensitivity of PET and specificity of MRI. 17, 25, 26 Crouser et al. 22 described the combination of late gadolinium enhancement and T2 signalling by MRI to help delineate areas of activity vs. scar in the myocardium. An analysis of the impact of specific imaging features (e.g. delayed enhancement on MRI or uptake on PET) on the likelihood of recovery or disease progression is beyond the scope of this manuscript, but necessitates further . The large size of our patient group is a significant strength of our study. Due to the retrospective nature of this analysis, reliance on clinical notes search and expert review, and differences that may exist in the way diagnoses are documented by multiple providers over two decades, it is possible that our search strategy did not capture all patients with CS. Our strict application of the diagnostic criteria for inclusion also resulted in the exclusion of some patients who were felt likely to have CS by the treating clinicians, as is presented in Figure 1 . Finally, patients who were not followed at these institutions longitudinally (for example, were seen once in consultation then returned to other providers for ongoing care) were also not included in this analysis. Ultimately, a large number of patients met criteria for inclusion, allowing us to describe a wide range of disease manifestations and outcomes, as well as utilization of multiple therapeutic approaches. That heterogeneity ultimately impacts the comparisons that can be made across outcomes and individual therapies. The retrospective approach also limits the conclusions here, as does the small total number of outcome events observed during the long period of follow-up. Due to these factors, and variable duration of follow-up, event proportions cannot be expressed as percentages, and multivariate modelling would not appropriate. The racial characteristics of this population may not reflect the distribution in other reports. The wide span of years evaluated likely impacted diagnostic modalities and therapeutic decisions over time as well.
Conclusions
Our large cohort of patients with CS managed at two academic medical centres highlights the variety of diagnostic and management modalities utilized in clinical practice. Prospective investigations are needed to determine which CS patients would most benefit from immunosuppressive therapy, which agent(s) should be employed, and how long they should continue. As disease manifestations appeared to be the most important factors in predicting outcomes, it may be appropriate for future studies to stratify and analyse patients by specific clinical features of CS, rather than CS as a whole. Conflict of interest: none declared.
